Skip to main content

Second Primary Malignancy Risk Increased After Cutaneous B-Cell Lymphoma

Medically reviewed by Carmen Pope, BPharm. Last updated on April 3, 2024.

By Elana Gotkine HealthDay Reporter

WEDNESDAY, April 3, 2024 -- Patients with primary cutaneous B-cell lymphomas (PCBCLs) have an increased risk for second primary malignancies (SPMs), according to a study published online March 19 in the Journal of the American Academy of Dermatology.

Lauren Banner, from Thomas Jefferson University in Philadelphia, and colleagues used the Surveillance, Epidemiology, and End Results database from 2000 to 2020 to generate a cohort of 5,435 PCBCL patients to examine their risk for development of subsequent cancers, defined as SPM.

The researchers found that 16 percent of the patients received diagnoses of a second malignancy, which was higher than in the general population (standardized incidence ratio, 1.54). Women had an increased risk for thyroid, renal, and lung cancers (standardized incidence ratios, 3.06, 2.13, and 1.69, respectively). Men had the highest risk for melanoma, bladder, and prostate cancers (standardized incidence ratios, 1.49, 1.42, and 1.29, respectively). The risks for all SPMs were highest within the first year of PCBCL diagnosis and decreased with time (standardized incidence ratios within the first year: 21.11 for thyroid cancer for women; 2.09 for prostate cancer for men). The risk for all SPMs decreased with patient age; a threefold higher risk for all SPMs was seen for patients aged 40 to 49 years (standardized incidence ratio, 3.07).

"Dermatologists may educate PCBCL patients on the symptoms and screening guidelines for these six malignancies and refer for further consultation if concerning symptoms are present," the authors write.

Abstract/Full Text (subscription or payment may be required)

Disclaimer: Statistical data in medical articles provide general trends and do not pertain to individuals. Individual factors can vary greatly. Always seek personalized medical advice for individual healthcare decisions.

© 2024 HealthDay. All rights reserved.

Posted April 2024

Read this next

American Society of Clinical Oncology, May 30-June 4

The annual meeting of the American Society of Clinical Oncology was held from May 30 to June 4 in Chicago and hosted more than 34,000 participants from around the world, including...

New Clinical Score Can Predict Immune Checkpoint Blockade Response

MONDAY, June 10, 2024 -- For patients with cancer, a novel clinical score using a six-feature regression model can predict immune checkpoint blockade (ICB) response probability...

ASCO: Germline Variation Does Not Predict Taxane-Induced Peripheral Neuropathy

FRIDAY, June 7, 2024 -- Germline variation does not predict the risk of taxane-induced peripheral neuropathy (TIPN) in Black women receiving paclitaxel (once weekly) or docetaxel...

More news resources

Subscribe to our newsletter

Whatever your topic of interest, subscribe to our newsletters to get the best of Drugs.com in your inbox.